Abstract:Uterine smooth muscle tumors (USMTs) consist of a group of histologically heterogeneous and clinically diverse diseases ranging from malignant leiomyosarcoma (LMS) to benign leiomyoma (ULM). The genetic alterations in LMS are complex, with some genetic alterations present in both LMS and other atypical histologic variants of USMT. In this study, we reviewed 119 USMTs with a diagnosis of LMS, smooth muscle tumor of uncertain malignant potential, atypical leiomyomas/leiomyoma with bizarre nuclei, and cellular leiomyoma, as well as 46 ULMs and 60 myometrial controls. We selected 17 biomarkers highly relevant to LMS in 4 tumorigenic pathways including steroid hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]), cell cycle/tumor suppressor genes, AKT pathway markers, and associated oncogenes. ER and PR expression was significantly lower in LMS than smooth muscle tumor of uncertain malignant potential, atypical leiomyomas/leiomyoma with bizarre nuclei, cellular leiomyoma, and ULM (P < .01). Sixty-five percent of LMSs showed complete loss of ER, and 75% of LMSs showed complete loss of PR. All cell cycle genes were differentially expressed in different types of tumor, but significant overlap was noted. More than 75% of LMSs had Ki-67 index greater than 33%, and only 5% in all other types of USMT. Expression of the selected oncogenes varied widely among different types of USMT. PR positivity and p53 had a borderline association with progression-free survival (P = .055 for PR and P = .0847 for p53). Furthermore, high PR expression was significantly associated with a longer overall survival (P = .0163, hazard ratio 0.198). Cell proliferative indices (Ki-67) and sex steroid hormone receptors were the most valuable markers in differentiating LMS from other USMT variants.

Expression of P16~(INK4A), CDK4 and Cyclin D1 Protein in Uterine Smooth Muscle Tumors

Expression and Clinical Significance of Small Ubiquitin-Like Modifier-1 and P53 Protein in Uterine Leiomyosarcoma

STMN1 and MKI67 Are Upregulated in Uterine Leiomyosarcoma and Are Potential Biomarkers for Its Diagnosis

Expression and clinical significance of STAT3 and downstream gene CyclinD1 in uterine leiomyoma

Potential diagnostic biomarkers for human mesenchymal tumors, especially LMP2/b1i and cyclin E1 differential expression

[The Significance of P16, Cyclin D1 and Prb Expression in Soft Tissue Leiomyosarcoma].

Diagnostic Value Of Progesterone Receptor, P16, P53 And Phh3 Expression In Uterine Atypical Leiomyoma

Expression of tumor suppressor gene p15, p16 in leiomyosarcoma of soft tissue

A study on the clinico-pathological characteristics and expression of p53,PCNA in uterine borderline leiomyoma

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers

Expression of HMGI-C and HMGI(Y) in Uterine Leiomyoma

The selected biomarker analysis in 5 types of uterine smooth muscle tumors.

EXPRESSION OF P53 AND Rb GENES IN HUMAN UTERINE LEIOMYOMA

Expression of apoptosis inhibitor Survivin and apoptosis protease Caspase-3 in uterine smooth muscle tumour

Myxoid Leiomyosarcoma of the Uterus: a Clinicopathological and Immunohistochemical Study of 10 Cases.

Expressions of MCM5 and P16INK4A in Cervical Squamous Cell Carcinoma

The Hypermethylation and Protein Expression of P16(Ink4a) and Dna Repair Gene O-6-Methylguanine-Dna Methyltransferase in Various Uterine Cervical Lesions

Expression of Β-Catenin and WT1 in Uterine Mesenchymal Tumors and Their Clinical Significance

Expression Profiling of Protein Tyrosine Kinases and Their Ligand Activators in Leiomyoma Uteri.

Expression and Clinical Values of HPV L1 and P16ink4a Protein in Uterine Cervical Lesions

Expressions of P16 and P15 Genes in Uterine Endometrial Carcinoma